TY - JOUR
T1 - Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers
T2 - a longitudinal MRI study
AU - Chen, Qin
AU - Boeve, Bradley F.
AU - Senjem, Matthew
AU - Tosakulwong, Nirubol
AU - Lesnick, Timothy
AU - Brushaber, Danielle
AU - Dheel, Christina
AU - Fields, Julie
AU - Forsberg, Leah
AU - Gavrilova, Ralitza
AU - Gearhart, Debra
AU - Graff-Radford, Jonathan
AU - Graff-Radford, Neill
AU - Jack, Clifford R.
AU - Jones, David
AU - Knopman, David
AU - Kremers, Walter K.
AU - Lapid, Maria
AU - Rademakers, Rosa
AU - Ramos, Eliana Marisa
AU - Syrjanen, Jeremy
AU - Boxer, Adam L.
AU - Rosen, Howie
AU - Wszolek, Zbigniew K.
AU - Kantarci, Kejal
N1 - Funding Information:
The authors extend their appreciation to the staff of all centers, and particularly to their patients and their families for their participation in this protocol. This work is funded by United States Department of Health & Human Services National Institutes of Health (NIH) - USA ( U01 AG045390 , U54 NS092089, U24 AG021886, U01 AG016976, R01 AG 40042), and Bluefield Foundation. The funding sources had no role in study design, collection, analysis, interpretation, or decision to submit this paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Authors' contributions: Qin Chen helped in design or conceptualization of the study, data collection, analysis and interpretation of the data, and drafting the manuscript. Bradley F. Boeve helped in data collection, analysis or interpretation of the data, revising the manuscript, and study funding. Matthew Senjem helped in analysis or interpretation of the data and revising the manuscript. Nirubol Tosakulwong helped in analysis or interpretation of the data and revising the manuscript. Timothy Lesnick helped in analysis or interpretation of the data and revising the manuscript. Danielle Brushaber helped in analysis or interpretation of the data and revising the manuscript. Christina Dheel helped in analysis or interpretation of the data and revising the manuscript. Julie Fields helped in data collection, analysis or interpretation of the data and revising the manuscript. Leah Forsberg helped in data collection, analysis or interpretation of the data, and revising the manuscript. Ralitza Gavrilova helped in data collection, analysis or interpretation of the data and revising the manuscript. Debra Gearhart helped in data collection, analysis or interpretation of the data and revising the manuscript. Jonathan Graff-Radford helped in data collection, analysis or interpretation of the data, and revising the manuscript. Neill Graff-Radford helped in data collection, analysis or interpretation of the data and revising the manuscript. Clifford R. Jack helped in analysis or interpretation of the data and revising the manuscript. David Jones helped in data collection, analysis or interpretation of the data and revising the manuscript. David Knopman helped in data collection, analysis or interpretation of the data and revising the manuscript. Walter K. Kremers helped in analysis or interpretation of the data and revising the manuscript. Maria Lapid helped in data collection, analysis or interpretation of the data and revising the manuscript. Rosa Rademakers helped in data collection, analysis or interpretation of the data and revising the manuscript. Eliana Marisa Da Silva Ramos helped in analysis or interpretation of the data and revising the manuscript. Jeremy Syrjanen helped in data collection, analysis or interpretation of the data and revising the manuscript. Adam L. Boxer helped in analysis or interpretation of the data and revising the manuscript. Howie Rosen helped in analysis or interpretation of the data and revising the manuscript. Zbigniew K. Wszolek helped in analysis or interpretation of the data, revising the manuscript, communicating with the research subjects, and study funding. Kejal Kantarci helped in design or conceptualization of the study, data collection, analysis and interpretation of the data, drafting the manuscript, and study funding. Appendix A
Funding Information:
Chen Q. reports no competing interests. Boeve B. has served as an investigator for clinical trials sponsored by GE Healthcare and Axovant. He receives royalties from the publication of a book entitled Behavioral Neurology of Dementia (Cambridge Medicine, 2009, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and the Little Family Foundation. Senjem M. reports no competing interests. Tosakulwong N. reports no competing interests. Lesnick T. reports no competing interests. Brushaber D. reports no competing interests. Dheel C. reports no competing interests. Fields J. receives research support from NIH. Forsberg L. receives research support from NIH. Gavrilova R. receives research support from NIH. Gearhart D. reports no competing interests. Graff-Radford J. receives research support from the NIH. Graff-Radford N. receives royalties from UpToDate and has participated in multicenter therapy studies by sponsored by Biogen, TauRx, AbbVie, Novartis, and Lilly. He receives research support from NIH. Jack C.R., Jr., consults for Eli Lilly and serves on an independent data monitoring board for Roche but he receives no personal compensation from any commercial entity. He receives research support from the NIH. Jones D. receives research support from NIH and the Minnesota Partnership for Biotechnology and Medical Genomics. Knopman D. serves on the DSMB of the DIAN-TU study, is a site PI for clinical trials sponsored by Biogen, Lilly, and the University of Southern California, and is funded by NIH. Kremers W. receives research funding from AstraZeneca, Biogen, Roche, DOD, and NIH. Lapid M reports no competing interests. Rademakers R. receives research funding from NIH and the Bluefield Project to Cure Frontotemporal Dementia. Ramos E.M. reports no disclosures relevant to the manuscript. Ramos E. reports no competing interests. Syrjanen J. reports no competing interests. Boxer A. receives research support from NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer's Drug Discovery Foundation, and the Alzheimer's Association. He has served as a consultant for Aeton, Abbvie, Alector, Amgen, Arkuda, Ionis, Iperian, Janssen, Merck, Novartis, Samumed, Toyama, and UCB and received research support from Avid, Biogen, BMS, C2N, Cortice, Eli Lilly, Forum, Genentech, Janssen, Novartis, Pfizer, Roche, and TauRx. Rosen H has received research support from Biogen Pharmaceuticals, has consulting agreements with Wave Neuroscience and Ionis Pharmaceuticals, and receives research support from NIH. Wszolek Z. is supported by the NIH, Mayo Clinic Center for Regenerative Medicine, received the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch, The Sol Goldman Charitable Trust, and Donald G. and Jodi P. Heeringa. He has also received grant funding support from Allergan, Inc (educational grant), and Abbvie (medication trials). Kantarci K. served on the Data Safety Monitoring Board for Takeda Global Research & Development Center, Inc; data monitoring boards of Pfizer and Janssen Alzheimer Immunotherapy; research support from the Avid Radiopharmaceuticals, Eli Lilly, the Alzheimer's Drug Discovery Foundation, and NIH.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/4
Y1 - 2020/4
N2 - Loss-of-function mutations in the progranulin gene (GRN) are one of the major causes of familial frontotemporal lobar degeneration. Our objective was to determine the rates and trajectories of lobar cortical atrophy from longitudinal structural magnetic resonance imaging in both asymptomatic and symptomatic GRN mutation carriers. Individuals in this study were from the ADRC and LEFFTDS studies at the Mayo Clinic. We identified 13 GRN mutation carriers (8 asymptomatic, 5 symptomatic) and noncarriers (n = 10) who had at least 2 serial T1-weighted structural magnetic resonance images and were followed annually with a median of 3 years (range 1.0–9.8 years). Longitudinal changes in lobar cortical volume were analyzed using the tensor-based morphometry with symmetric normalization (TBM-SyN) algorithm. Linear mixed-effect models were used to model cortical volume change over time among 3 groups. The annual rates of frontal (p < 0.05) and parietal (p < 0.01) lobe cortical atrophy were higher in asymptomatic GRN mutation carriers than noncarriers. The symptomatic GRN mutation carriers also had increased rates of atrophy in the frontal (p < 0.01) and parietal lobe (p < 0.01) cortices than noncarriers. In addition, greater rates of cortical atrophy were observed in the temporal lobe cortices of symptomatic GRN mutation carriers than noncarriers (p < 0.001). We found that a decline in frontal and parietal lobar cortical volume occurs in asymptomatic GRN mutation carriers and continues in the symptomatic GRN mutation carriers, whereas an increased rate of temporal lobe cortical atrophy is observed only in symptomatic GRN mutation carriers. This sequential pattern of cortical involvement in GRN mutation carriers has important implications for using imaging biomarkers of neurodegeneration as an outcome measure in potential treatment trials involving GRN mutation carriers.
AB - Loss-of-function mutations in the progranulin gene (GRN) are one of the major causes of familial frontotemporal lobar degeneration. Our objective was to determine the rates and trajectories of lobar cortical atrophy from longitudinal structural magnetic resonance imaging in both asymptomatic and symptomatic GRN mutation carriers. Individuals in this study were from the ADRC and LEFFTDS studies at the Mayo Clinic. We identified 13 GRN mutation carriers (8 asymptomatic, 5 symptomatic) and noncarriers (n = 10) who had at least 2 serial T1-weighted structural magnetic resonance images and were followed annually with a median of 3 years (range 1.0–9.8 years). Longitudinal changes in lobar cortical volume were analyzed using the tensor-based morphometry with symmetric normalization (TBM-SyN) algorithm. Linear mixed-effect models were used to model cortical volume change over time among 3 groups. The annual rates of frontal (p < 0.05) and parietal (p < 0.01) lobe cortical atrophy were higher in asymptomatic GRN mutation carriers than noncarriers. The symptomatic GRN mutation carriers also had increased rates of atrophy in the frontal (p < 0.01) and parietal lobe (p < 0.01) cortices than noncarriers. In addition, greater rates of cortical atrophy were observed in the temporal lobe cortices of symptomatic GRN mutation carriers than noncarriers (p < 0.001). We found that a decline in frontal and parietal lobar cortical volume occurs in asymptomatic GRN mutation carriers and continues in the symptomatic GRN mutation carriers, whereas an increased rate of temporal lobe cortical atrophy is observed only in symptomatic GRN mutation carriers. This sequential pattern of cortical involvement in GRN mutation carriers has important implications for using imaging biomarkers of neurodegeneration as an outcome measure in potential treatment trials involving GRN mutation carriers.
KW - Asymptomatic
KW - Frontotemporal dementia
KW - GRN
KW - Longitudinal
KW - Magnetic resonance image
UR - http://www.scopus.com/inward/record.url?scp=85077522637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077522637&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2019.12.004
DO - 10.1016/j.neurobiolaging.2019.12.004
M3 - Article
C2 - 31918955
AN - SCOPUS:85077522637
SN - 0197-4580
VL - 88
SP - 42
EP - 50
JO - Neurobiology of aging
JF - Neurobiology of aging
ER -